Related Experiment Videos
von Hippel-Lindau disease
1Division of Medical Genetics, University of Birmingham, Birmingham Women's Hospital, UK.
Medicine
|December 31, 1997
Summary
Von Hippel-Lindau disease results from mutations in the VHL gene, leading to tumor development. The VHL gene product (pVHL) regulates blood vessel growth by inhibiting hypoxia-inducible mRNAs like VEGF.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Von Hippel-Lindau (VHL) disease is an inherited cancer syndrome.
- It involves tumors in the central nervous system, retina, kidneys, and other organs.
- Germline mutations in the VHL tumor suppressor gene cause VHL disease.
Purpose of the Study:
- To explain the vascular nature of VHL-associated tumors.
- To investigate the role of the VHL gene product (pVHL) in regulating gene expression.
- To explore the molecular mechanisms underlying VHL disease pathogenesis.
Main Methods:
- The study reviews existing research on VHL disease and the VHL gene.
- It discusses the interaction of pVHL with elongins B/C and cullin 2 (Cul2).
- It proposes a model involving ubiquitination of RNA-binding proteins.
Main Results:
- The VHL gene product (pVHL) inhibits hypoxia-inducible mRNAs, including vascular endothelial growth factor (VEGF) mRNA, under normal oxygen conditions.
- pVHL's function is linked to its binding with elongin B, elongin C, and cullin 2 (Cul2).
- Elongin C and Cul2 are implicated in targeting proteins for ubiquitination and degradation.
Conclusions:
- pVHL's inhibition of VEGF mRNA accumulation explains the high vascularity of VHL tumors.
- pVHL interacts with the elongin/Cul2 complex, suggesting a role in protein regulation.
- A potential model proposes that pVHL influences the ubiquitination of RNA-binding proteins, affecting mRNA stability.